| |
All patients
|
Supine
|
Semi-recumbent
|
p-value*
|
|---|
|
n
|
69
|
33
|
36
| |
|---|
|
Age
|
62 ± 14
|
64 ± 16
|
61 ± 13
|
NS
|
|
Males (%)
|
42 (61)
|
19 (58)
|
23 (64)
|
NS
|
|
Smoking status
| | | | |
|
- Current smokers (%)
|
15 (22)
|
9 (27)
|
6 (17)
|
NS
|
|
- Ex-smokers (%)
|
33 (48)
|
16 (49)
|
17 (47)
|
NS
|
|
- Non-smokers (%)
|
21 (30)
|
8 (24)
|
13 (36)
|
NS
|
|
Inpatients (%)
|
26 (38)
|
11 (33)
|
15 (42)
|
NS
|
|
Baseline SpO2
|
97.0 ± 2.2
|
96.9 ± 2.4
|
97.1 ± 1.9
|
NS
|
|
Baseline pulse rate (/min)
|
77 ± 13
|
76 ± 13
|
77 ± 13
|
NS
|
|
% predicted FEV1
|
70 ± 19
|
67 ± 21
|
74 ± 17
|
NS
|
|
% predicted FVC
|
78 ± 17
|
79 ± 19
|
77 ± 14
|
NS
|
|
Oral route (%)
|
31 (45)
|
15 (45)
|
17 (47)
|
NS
|
|
Initial phase (min)
|
3.7 ± 1.3
|
3.9 ± 1.5
|
3.6 ± 1.1
|
NS
|
|
Cough rate (/min)
|
4.8 ± 3.7
|
6.1 ± 4.5
|
3.6 ± 2.3
|
0.007
|
|
Sedative use
| | | | |
|
- Midazolam (mg)
|
3.5 ± 1.7
|
4.0 ± 2.0
|
3.1 ± 1.2
|
0.029
|
|
- Fentanyl (mcg)
|
79 ± 30
|
88 ± 28
|
70 ± 29
|
0.011
|
|
Nadir SpO2
|
93.4 ± 4.6
|
93.3 ± 4.3
|
93.6 ± 4.9
|
NS
|
|
Fall in SpO2
|
3.6 ± 4.2
|
3.6 ± 3.6
|
3.6 ± 4.7
|
NS
|
|
Peak pulse rate (/min)
|
92 ± 16
|
91 ± 17
|
94 ± 15
|
NS
|
|
Rise in pulse rate (/min)
|
16 ± 13
|
16 ± 12
|
16 ± 14
|
NS
|
|
Maximal O2 use (L/min)
|
3.0 ± 1.8
|
3.0 ± 2.1
|
3.0 ± 1.5
|
NS
|
|
Questionnaire†
| | | | |
|
- Nurse VAS discomfort
|
31 ± 26
|
39 ± 28
|
23 ± 21
|
0.01
|
|
- Patient VAS recall
|
49 ± 35
|
51 ± 35
|
47 ± 36
|
NS
|
|
- Patient VAS discomfort
|
24 ± 23
|
22 ± 23
|
27 ± 23
|
NS
|
|
- Patient VAS cough
|
33 ± 27
|
40 ± 28
|
28 ± 25
|
0.067
|
|
- Patient 1-4 repeat
|
1.2 ± 0.4
|
1.2 ± 0.4
|
1.1 ± 0.4
|
NS
|
- Values shown as mean ± SD or number (%).
- * p-values shown for comparisons between supine and semi-recumbent groups.
- † VAS responses measured in mm from the left end of the visual analogue scale.
- FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; SpO2, oxygen saturation; VAS, visual analogue scale; NS, not significant at > 0.05.
